Allen & Overy advises on Immunotech Biopharm’s global offering and listing on the Hong Kong Stock Exchange
10 July 2020
Immunotech Biopharm is a cancer immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T-cell immunotherapy for over 13 years.
CCB International Capital Limited and Guosen Securities (HK) Capital Company Limited acted as the joint sponsors. CCB International Capital Limited, Guosen Securities (HK) Capital Company Limited and Haitong International Securities Company Limited acted as the joint global coordinators.
The Allen & Overy team comprises Corporate partner Lina Lee, International Capital Markets partner Kung-Wei Liu, and other members including Zoe Guan, Arthur Wong, Shue Sing Churk, Veronica Tse, Xunming Lim, Martin Hui and Curtis Fung. Zhen Gu from Allen & Overy Lang Yue (FTZ) Joint Operation Office also contributed. The joint operation brings together Lang Yue’s high-quality execution capability and Allen & Overy’s international platform, to provide clients with seamless PRC and international legal services across a wide range of capabilities.